Tech Company Financing Transactions
Lactiga Therapeutics Funding Round
Lactiga Therapeutics secured a $1.6 million Series D investment round on 9/21/2022. Backers included 1517 Fund and private investors.
Transaction Overview
Company Name
Announced On
9/21/2022
Transaction Type
Venture Equity
Amount
$1,600,000
Round
Series D
Investors
1517 Fund (Lead Investor) (Zak Slayback)
Proceeds Purpose
This new capital will advance the research and development of our novel therapeutic antibodies that can represent the next generation of anti-infectives for patients who are unable to produce their own antibodies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 King St. West 6000
Toronto Ontario, M5X 1E2
Canada
Toronto Ontario, M5X 1E2
Canada
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world's most dangerous pathogens including SARS-CoV-2.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Co-Founder
Viraj Mane
Co-Founder
Rikin Mehta
Browse more venture capital transactions:
Prev: 9/21/2022: Loctax venture capital transaction
Next: 9/21/2022: Aura Bora venture capital transaction
Share this article
News on VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs